



FORM PTO-1449

Att. Docket No.: REG 900A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

1619

FEB 14 2003

RECEIVED

TECH CENTER 1600/2900

USSN : 10/055,842

Applicant: Gale, N.W., et al.

Date Filed: January 23, 2002

Title: Methods of Imaging and Targeting
Vasculature

Examiner: Not yet known

Group Art Unit: 1619

February 6, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
----------------------	------------------	---------------	-----------------------	---------------------	------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class/ Date Subclass	Translation Yes No
----------------------	--------------------	------	---------	----------------------------	----------------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

(Handwritten signature)
Kirsch, JE, 1991, "Basic principles of magnetic resonance contrast agents", Top Magn Reson Imaging 3:1-18

(Handwritten signature)
Wallis, F. and Gilbert, FJ, 1999, J R, "Magnetic resonance imaging in oncology: an overview", Coll Surg Edinb 44:117-125

(Handwritten signature)
Schiepers, C. and Hoh, CK, 1998, "Positron emission tomography as a diagnostic tool in oncology", Eur Radiol 8:1481-1494

(Handwritten signature)
Ferrand, SK, et al., 1999, "What is new in nuclear medicine imaging?", Surg Oncol Clin N Am 8:185-204

(Handwritten signature)
Wang, H.U., et al., 1998, "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4", Cell 93:741-753.

11/18/01

Information Disclosure Statement Form 1449
Gale, N. W., et al.
USSN 10/055,842

109
Gerety, S.S., et al., 1999, "Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development", Mol Cell 4:403-414.

DP
Adams, R.H., et al., 1999, "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis", Genes & Dev 13:295-306.

EXAMINER
CONSIDERED

DATE

11/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:

Linda O. Palladino
Linda O. Palladino
Reg. No. 45,636
Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400